CORBEVAXTM is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against COVID-19
Biological E. Limited received the approval for restricted use in an emergency situation in adolescents aged 12 to less than 18 years based on interim results (of the ongoing phase II/III clinical study).
Last September, BE received approval to conduct a Phase II/III clinical trial on CORBEVAXTM in children and adolescents aged 5 to 18 years. Based on the no-objection certificate, BE initiated the clinical study in October 2021 and evaluated the available safety and immunogenicity results of the ongoing phase II/III study, which indicated that the vaccine is safe and immunogenic.
The CORBEVAXTM vaccine is administered through intramuscular route with two doses scheduled 28 days apart and is stored at 2 to 8 degrees’ Celsius temperature and presented as 0.5 ml (single dose) and 5 ml (10 doses) vial and 10 mL (20 doses) vial pack